UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.urogen.com
Company Research
Source: GlobeNewswire
PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the launch of its “LG-UTUC Luminaries” initiative, recognizing clinicians and institutions demonstrating leadership, expertise, and a commitment to advancing low-grade upper tract urothelial cancer (LG-UTUC) care. LG-UTUC is a rare form of cancer affecting an estimated 6,000-7,000 patients each year in the U.S., which represents approximately 40% of patients diagnosed in the U.S. annually with UTUC. While typically noninvasive, it often recurs and may require repeated endoscopic procedures or radical surgery to remove the kidney and ureter, underscoring a continued need for guideline-recommended kidney-sparing care approaches. “Through the LG-UTUC Luminaries initiative, we are honored to recognize the clinicians and institutions redefining what is possib
Show less
Read more
Impact Snapshot
Event Time:
URGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
URGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
URGN
News
- Urogen Pharma (URGN) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $40.00 price target on the stock.MarketBeat
- Why The UroGen Pharma (URGN) Investment Story Is Shifting As Analysts Hold Fair Value Steady [Yahoo! Finance]Yahoo! Finance
- Urogen Pharma (URGN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $33.00 price target on the stock.MarketBeat
- Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURIGlobeNewswire
- UroGen Applauds BCAN's New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence [Yahoo! Finance]Yahoo! Finance
URGN
Earnings
- 3/2/26 - Beat
URGN
Sec Filings
- 3/2/26 - Form 10-K
- 3/2/26 - Form 8-K
- 3/2/26 - Form 8-K
- URGN's page on the SEC website